Education
About Us
Working with TipRanks
Follow Us
Allergy Therapeutics PLC (GB:AGY)
LSE:AGY
AGY Stock Chart & Stats
11.80p
-0.04p(-0.55%)
At close: 4:00 PM EST
11.80p
-0.04p(-0.55%)
Day’s Range― - ―
52-Week Range5.00p - 12.10p
Previous CloseN/A
Volume22.64K
Average Volume (3M)460.33K
Market Cap
£718.55M
Enterprise Value588.57M
Total Cash (Recent Filing)£12.79M
Total Debt (Recent Filing)£60.09M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,141,440,000
10 Day Avg. Volume433,490
30 Day Avg. Volume460,334
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)-13.44
Price to Sales (P/S)6.88
P/FCF Ratio-11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£68.00M
Bulls Say, Bears Say
Bulls Say
Focused Immunotherapy PortfolioA focused portfolio of allergy immunotherapies and vaccines creates clinical and regulatory expertise and product differentiation. That specialization builds durable barriers to entry, supports long-term product relevance to clinicians, and underpins sustained commercial focus.
Established Distribution And PartnershipsDirect sales to healthcare providers combined with partnerships and distributor relationships diversify commercial channels. This durable go-to-market network improves reach, reduces single-channel risk, and increases odds of steady product uptake across regions over months.
R&D Pipeline And Licensing PotentialAn active clinical pipeline and potential licensing routes create multiple strategic pathways: partnership funding, milestone revenue, or licensing deals. These options can provide non-dilutive or revenue-generating outcomes that materially change medium-term cash flows and commercial breadth.
Bears Say
Declining Revenue TrendA roughly 11% revenue decline signals weakening core sales and deteriorating market traction. Persistent top-line contraction erodes scale economics, pressures margins and reduces internal funding capacity for R&D or sales expansion, making recovery dependent on new product or partner wins.
Large Persistent LossesDeep negative margins and sustained losses consume capital and limit reinvestment. Persistent unprofitability increases reliance on external financing, constraining strategic flexibility and potentially delaying commercialization investments or scaling of commercial operations.
Weak Balance Sheet And Cash GenerationNegative shareholders' equity, high leverage and negative operating/free cash flows indicate constrained liquidity and refinancing risk. This limits ability to fund trials, expand sales capabilities, or absorb setbacks without dilutive or costly financing, harming long-term execution.
Allergy Therapeutics News
AGY FAQ
What was Allergy Therapeutics PLC’s price range in the past 12 months?
Allergy Therapeutics PLC lowest share price was 5.00p and its highest was 12.10p in the past 12 months.
What is Allergy Therapeutics PLC’s market cap?
Allergy Therapeutics PLC’s market cap is £718.55M.
When is Allergy Therapeutics PLC’s upcoming earnings report date?
Allergy Therapeutics PLC’s upcoming earnings report date is Sep 30, 2026 which is in 214 days.
How were Allergy Therapeutics PLC’s earnings last quarter?
Currently, no data Available
Is Allergy Therapeutics PLC overvalued?
According to Wall Street analysts Allergy Therapeutics PLC’s price is currently Overvalued.
Does Allergy Therapeutics PLC pay dividends?
Allergy Therapeutics PLC does not currently pay dividends.
What is Allergy Therapeutics PLC’s EPS estimate?
Allergy Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Allergy Therapeutics PLC have?
Allergy Therapeutics PLC has 6,141,440,000 shares outstanding.
What happened to Allergy Therapeutics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Allergy Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:AGY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allergy Therapeutics Stock Smart Score
Company Description
Allergy Therapeutics PLC
Allergy Therapeutics (AGY) is a biotechnology company focused on the development and commercialization of innovative allergy immunotherapy products. The company specializes in providing treatments for allergic conditions, primarily targeting pollen, dust mites, and animal allergens. Its core product offerings include allergy vaccines and immunotherapy solutions designed to alleviate symptoms and improve the quality of life for patients suffering from allergies. AGY operates primarily within the healthcare sector, leveraging cutting-edge research to develop effective therapies for allergy sufferers worldwide.
Technical Analysis
Animalcare
―
Hikma Pharmaceuticals
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---